Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It works by binding directly to the HIV-1 reverse transcriptase enzyme and inhibiting its RNA-dependent and DNA-dependent DNA polymerase activities, thereby blocking viral replication. Nevirapine is not effective against HIV-2. It is indicated for use in adults and children as young as 15 days old and may also be used to prevent mother-to-child transmission of HIV during childbirth. Resistance can develop rapidly if used as monotherapy or if viral replication is not fully suppressed[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nevirapine.